Package Leaflet: Information for the User
Malaway 250 mg/100 mg Film-Coated Tablets EFG
atovaquone/hydrochloride of proguanil
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
-This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
1.What Malaway is and what it is used for
2.What you need to know before you start taking Malaway
3.How to take Malaway
4.Possible side effects
5.Storage of Malaway
6.Contents of the pack and additional information
Malaway belongs to a group of medications known asantimalarials.It contains two active principles, atovaquone andhydrochloride of proguanil.
Malaway has two uses:
Malaria is transmitted by the bite of an infected mosquito, which introduces the malaria parasite(Plasmodium falciparum)into the blood. Malaway prevents malaria by killing this parasite. For people who have already been infected with malaria, Malaway also kills these parasites.
Protect yourself from contracting malaria
Anyone, regardless of age, can contract malaria. It is a serious disease, but it is preventable. Even when taking Malaway, it is very important to take precautions to avoid mosquito bites.
If you need more advice,consult your doctor or pharmacist.
Even with all necessary precautions, it is possible to contract malaria.Some types of malaria infection can take a long time to cause symptoms; therefore, the disease may not begin until several days, weeks, or even months after returning from travel.
Consult a doctor immediately if you have symptomssuch as fever, headache, chills, or fatigue, after returning from abroad.
Do not take Malaway
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Toprevent malaria:
To treat malaria:
Other medications and Malaway
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Some medications may affect how Malaway works, or Malaway may enhance or reduce the effect of other medications used at the same time. These include:
Notify your doctor if you are taking any of them. Your doctor may decide that Malaway is not suitable for you, or that you need additional checks while taking it.
REMEMBER to consult with your doctor if you start taking any other medication while taking Malaway.
Taking Malaway with food and drinks
Take Malaway with food or a lactose drink, if possible. This will increase the amount of Malaway that your body can absorb, and make your treatment more effective.
It is preferable not to break the tablets.
Pregnancy and breastfeeding
If you are pregnant, or in a breastfeeding period, believe you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication. Do not take Malaway unless your doctor recommends it.
Do not breastfeed while taking Malaway, as the components of Malaway may pass into breast milk and harm your baby.
Driving and using machines
If you feel dizzy, do not drive. Malaway makes some people feel dizzy. If this happens to you, do not drive, use machines, or participate in activities that may put you or others at risk.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist.If in doubt, consult your doctor or pharmacist again.
Take Malaway with food or a milk-based beverage whenever possible.
It is recommended to take Malaway every day at the same time.
Prevention of malaria:
The usual dose in adults and adolescents weighing more than 40 kg is one tablet per day, taken as indicated below.
For children, consult your doctor.
Malaway is not recommended for malaria prevention in children, or in adults or adolescents weighing less than 40 kg.
In your country, there may be a different type of Malaway tablet available for children.
For malaria prevention in adults:
Take all the Malaway tablets in the treatment for maximum protection.
Stopping it early implies a risk of contracting malaria, as 7 days are needed to ensure the death of the parasites that may have been in your body from the mosquito bite.
Treatment of malaria:
The recommended dose in adults is 4 tablets per day for 3 days.
For children weighing 11 kg or more:
Malaway is not recommended for malaria treatment in children weighing less than 11 kg.
For children weighing less than 11 kg, consult your doctor. There may be another type of Malaway tablet available for children in your country.
If you take more Malaway than you should
Contact your doctor or pharmacist for help and, if possible, show them the medication packaging.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91.562.04.20 indicating the medication and the amount ingested.
If you forget to take Malaway
It is very important to take the complete Malaway treatment. If you forget a dose, do not worry. Take the next dose as soon as you remember. Then continue the treatment as you were doing before.Do not take a double dose to compensate for the missed doses.
Do not interrupt the Malaway treatment without consulting your doctor
Continue taking Malawayfor 7 days after returning from a malaria-free area. Take the complete Malaway treatment for maximum protection. If you interrupt it early, you put yourself at risk of contracting malaria, as 7 days are needed to ensure the death of the parasites that may have been in your body from the mosquito bite.
Consult your doctor or pharmacist for advice.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Be aware of the following severe reactions. They have been observed in a reduced number of people, although their exact frequency is unknown.
Severe allergic reactions. The signs include:
If you experience any of these symptoms, contact a doctor immediately. Stop taking Malaway.
Severe skin reactions:
If you detect any of these symptoms, contact a doctor urgently.
Most other reported side effects have been mild and did not last long.
Very common side effects (may affect more than 1 in 10 patients):
Common side effects (may affect between 1 and 10 in 100 patients):
Common side effects that may be discovered in blood tests:
Rare side effects (may affect between 1 and 10 in 1,000 patients)
These may affect up to 1 in 100 people:
Rare side effects that may be discovered in blood tests:
Very rare side effects: may affect between 1 and 10 in 10,000 people
Other side effects:Other side effects have occurred in a reduced number of people, although their frequency is unknown.
Other side effects that may appear in blood tests:
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist. Even if it is a possible side effect that does not appear in this leaflet, you can also report it directly through theSpanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears on the box and the blister packafter CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. Ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Malaway
- The active principles are atovaquone and proguanil hydrochloride.
Cada comprimido contiene 250 mg de atovaquona y 100 mg de hidrocloruro de proguanil.
- The other components are:
Core of the tablet : poloxamer 188, microcrystalline cellulose, hydroxypropylmethylcellulose with low degree of substitution, povidone K30, sodium carboxymethylcellulose (type A) (from potato), anhydrous colloidal silica, magnesium stearate.
Coating : hypromellose, titanium dioxide (E171), iron oxide red (E172), Macrogol 400, Macrogol 8000.
Appearance of the product and contents of the package
Malaway are brown-pink, round, biconvex, beveled-edge tablets, coated with a film and marked on one face with "404" and with "G" on the other.
Malaway is presented in PVC/PVDC (transparent) blisters and rigid and tempered aluminum PVC/PVDC sheets.
Package sizes: 12, 24, 36, 60 tablets.
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer and responsible manufacturer
Marketing authorization holder:
Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany
Responsible manufacturer:
Glenmark Pharmaceuticals s.r.o.
Fibíchova 143
566 17 Vysoké Mýto
Czech Republic
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
Viso Farmacéutica, S.L.U.
c/ Retama 7, 7ª Planta
28045 Madrid
Spain
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Country | Medicinal product name |
Germany | Atovaquon/Proguanilhydrochlorid Glenmark 250 mg /100 mg Filmtabletten |
Austria | Atovaquon/Proguanilhydrochlorid Glenmark 250 mg/100 mg Filmtabletten |
Denmark | Atovaquone/Proguanil Glenmark 250 mg /100 mg Filmovertrukne tabletter |
Spain | Malaway 250 mg/100 mg comprimidos recubiertos con película EFG |
France | Atovaquone/Proguanil BGR 250 mg /100 mg comprimé pelliculé |
Ireland | Atovaquone/Proguanil Hydrochloride 250 mg /100 mg Film-coated tablets |
Norway | Atovaquone/Proguanil Glenmark |
Netherlands | Atovaquone/Proguanilhydrochloride Glenmark 250 mg /100 mg Filmomhulde Tabletten |
Poland | Falcimar |
Sweden | Atovaquone/Proguanil Glenmark 250/100 mg filmdragerade tabletter |
Last review date of this leaflet: December 2023.
The detailed information about this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) ( http://www.aemps.gob.es/ )
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.